What is Tympanogen?
Tympanogen, Inc. is at the forefront of developing innovative ear, nose, and throat (ENT) devices, leveraging proprietary gel technology. The company's flagship product, Perf-Fix, is engineered to revolutionize traditional tympanoplasty procedures, aiming to transform them into a swift, in-office treatment. This novel gel patch facilitates the regeneration of the complete tympanic membrane structure, reportedly achieving success rates comparable to conventional tympanoplasty, but with a significantly reduced application time of approximately 10 minutes and without the need for general anesthesia or margin preparation.
How much funding has Tympanogen raised?
Tympanogen has raised a total of $1M across 1 funding round:
Other Financing Round
$1M
Other Financing Round (2022): $1M with participation from NO/LA Angel Network
Key Investors in Tympanogen
NO/LA Angel Network
NO/LA Angel Network, also known as Gulf South Angels, is an investment network focused on providing financial backing and strategic mentorship to emerging companies. They leverage their members' extensive experience to offer guidance and business insights, fostering growth within their portfolio and network.
What's next for Tympanogen?
With the recent major strategic investment, Tympanogen is poised to accelerate its product development and market entry for Perf-Fix. This enterprise-level funding is expected to fuel the scaling of manufacturing capabilities, expand clinical validation efforts, and support the commercialization strategy. The company's focus on streamlining ENT procedures through its unique gel technology suggests a trajectory aimed at capturing significant market share by offering a more efficient and patient-friendly alternative to existing surgical interventions.
See full Tympanogen company page
